SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor. Interferon alfa-2b may interfere with the growth of the cancer cells. Combining interferon alfa-2b with SU5416 may be an effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of combining SU5416 and interferon alfa-2b in treating patients who have unresectable or metastatic kidney cancer.

Key facts

Study ID

NCT00006384

Run by

City of Hope Medical Center

Starts

2000-11-01

Expected to finish

2007-02-01

Last updated by the study team

2011-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cancer Center and Beckman Research Institute, City of Hope — Duarte, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.